Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ATOS)

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

GlobeNewswire 8 days ago

Sidoti Events, LLC's Virtual June Small-Cap Conference

Accesswire June 11, 2024

Atossa to Present at the Sidoti Small-Cap Investor Conference

GlobeNewswire June 5, 2024

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

GlobeNewswire May 28, 2024

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

GlobeNewswire May 15, 2024

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2024

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

GlobeNewswire May 7, 2024

Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV

Accesswire April 29, 2024

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

GlobeNewswire April 29, 2024
View More News ››

Opinion & Analysis (NDAQ:ATOS)

Coverage initiated on developer of potential breast cancer therapy competitor

Streetwise Reports January 31, 2018
View More Opinion ››

Bullboard Posts (NDAQ:ATOS)

Atossa Therapeutics Presents Data from 40mg Cohort of Phase

JUST IN: $ATOS Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate...
whytestocks - April 9, 2024

Excellent, YouTube analysis on Atossa!!

https://youtu.be/qDyE4zA02qU?si=lZUpAB1tA3HBbxli
BryceCanada - April 8, 2024

Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort

Just In: $ATOS Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z...
whytestocks - June 12, 2023

Atossa Appoints Life Sciences Financial and Operations Indus

NEWS: $ATOS Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial OfficerSEATTLE, June...
whytestocks - June 1, 2023

Dr Quay has issued a letter to shareholders.

It is worth reading as it provides an update on the recent activities of the company including its cash position.  B.
B8lair8 - February 4, 2023

Atossa has been moving well recently on ...

higher volume and higher share price. It's almost like somebody knows something.  
B8lair8 - January 18, 2023
View more Bullboard ››

E-Power Resources Inc

E-Power Resources Inc

E-Power Resources Inc. is a Canada-based exploration stage company. The Company is engaged principally in the acquisition ...
View More »